Senator Steve Daines, who represents Montana in the U.S. Senate, posted a series of messages on his official X account between September 22 and September 23, 2025. The tweets addressed topics ranging from healthcare for Native American communities to international cooperation in the railroad sector and concerns about abortion medication.
On September 22, Daines acknowledged federal support for healthcare facilities serving Montana’s Native American population. He wrote, “MT is home to 12 federally recognized tribes- thank you @POTUS & @SecKennedy for supporting IHS facilities in the Treasure State, so those living on our Indian reservations have access to high quality medical care.” Montana’s twelve federally recognized tribes are served by Indian Health Service (IHS) facilities, which provide medical care on reservations as part of the U.S. government’s trust responsibility to Native Americans.
Later that day, Daines expressed appreciation for international collaboration in transportation infrastructure. In a post dated September 22, he stated, “Thank you to the govt of Kazakhstan for your partnership and @POTUS for your leadership in helping our railroad industry!” The mention highlights ongoing efforts between the United States and Kazakhstan to strengthen economic ties and develop critical infrastructure such as railroads.
On September 23, Daines turned his attention to reproductive health policy debates. He criticized media coverage of mifepristone, an abortion medication approved by the FDA since 2000. Daines posted, “The media & pro-abortion advocates are falsely labeling the abortion pill as ‘safe.’ Read my op-ed about the real dangers of mifepristone below.” Mifepristone has been at the center of national discussions regarding its safety profile and regulatory status. While major medical organizations have found it generally safe when used as directed, some policymakers continue to raise concerns about its risks.
Daines’ public statements reflect broader policy debates involving tribal healthcare funding obligations under federal law, international partnerships aimed at bolstering U.S. infrastructure competitiveness—such as recent agreements with Kazakhstan—and ongoing disputes over reproductive rights legislation and pharmaceutical regulation.
